Clinical trial · Interventional
Cancer of the Lung And SeneScencE - Prospective Cohort 1
Identification of Aging Biomarkers for Better Tailoring of Cancer Treatment in Older Patients With Lung Cancer: a Multicenter Clinico-biological Cohort Study
NCT06923618CI-TRIAL-00098943CLASSE-P1recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective is to identify and assess the predictive value of ageing and senescence biomarkers (methylome, telomeres, inflammageing) and senescent cells in tissues to improve prognosis assessment older patients with locally or locally-advanced Non-Small Cell Lung Cancer (NSCLC).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood samples | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Unplanned hospitalizations within 12 months
- timeFrame
- 12 months post surgery
- description
- Number of unplanned hospitalizations within 12 months
Secondary outcomes (9)
- measure
- Mortality (all-cause) and cause-specific
- timeFrame
- Month 12 and Month 60 post surgery
- description
- Number of death (all-cause) and cause-specific at Month12 and Month 60
- measure
- Surgical Complications
- timeFrame
- Month 3 and Month 6 post surgery
- description
- Scores on the Clavien-Dindo Scale at Month 3 and Month 6
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients 70 years and over * Local or locally advanced (Clinic stage I-IIIA) NSCLC (clinically (or radiologically) suspected or histologically proven) * Surgical Curative Intent * Signed informed Consent (or signed by the curator or tutorship) * Affiliated to social security administrative care service Exclusion Criteria: * Synchronous cancer (histologically proven or strongly suspected non-lung cancer in the 6 months prior to inclusion (excluding basal cell cancer and prostate cancer with local treatment (radiotherapy or surgery) or active surveillance without systemic treatment (chemotherapy, hormone therapy)). * Subject deprived of liberty by judicial or administrative decision or patient under guardianship * Subject unable to understand the purpose and conditions of the study and unable to give consent
References
Publications (0)
Data not yet available
No reference posted for this study.